Fluidda is searching for an FRI analyst for our offices in Portugal. The FRI analyst’s main task is to implement and perform medical imaging analyses, through FLUIDDA’s proprietary Functional Respiratory Imaging (FRI) technology.
COPD is heterogeneous in its clinical manifestations and disease progression. Patients often have disease courses that are difficult to predict with readily available data, such as lung function testing. The... View Article
FLUIDDA introduces RespiNet, a model for automated segmentation of lung structures. At the ECR 2023 conference in Vienna, FLUIDDA presents their deep learning model for the segmentation of the lobes and airway... View Article
Pulmonary Hypertension (PH) patients need more treatment options, and it seems the Merck’s MK5475 inhaled drug is quite promising! FLUIDDA’s FRI technology showed substantial and homogeneous vasodilation throughout the lung... View Article
Nanopharm and FLUIDDA collaborate to enable alternative bioequivalence pathways for orally inhaled drug products To support generic drug companies in obtaining a market license for their orally inhaled drug products... View Article
In a recent publication in BMC Pulmonary Medicine (2022) 22:477, Ides et all. Investigated how body positioning can affect the regional distribution of lung ventilation and blood flow in healthy... View Article
MedImprove, a multidisciplinary medical center for respiratory revalidation which makes use of Fluidda’s propietary FRI technology, was featured in a recent publication of the Belgian daily newspaper ” De Standaard”.... View Article
Novel outcome measures for cystic fibrosis in a changing world Very recently Eline Lauwers, working for Fluidda in Belgium, defended a dissertation called: “Novel outcome measures for cystic fibrosis” to acquire... View Article
Will you be attending RSNA 2022, November 27th – December 1st in Chicago? Then you have a possibility to learn all about Broncholab®. Fluidda will be present to explain all features... View Article
The exact prevalence of COPD worldwide is largely unknown, but estimates have varied from 7-19%. The Burden of Obstructive Lung Disease (BOLD) study found a global prevalence of 10.1%. According to WHO estimates, 65 million people... View Article